<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38407">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01791322</url>
  </required_header>
  <id_info>
    <org_study_id>PM 01.1</org_study_id>
    <nct_id>NCT01791322</nct_id>
  </id_info>
  <brief_title>NovellusDx Tissue Collection Protocol</brief_title>
  <official_title>An Observational Study to Assess the Oncogenic Status of Colorectal Cancer Patients That Have Undergone Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovellusDx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NovellusDx</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      NovellusDx is developing a diagnostic platform for the early detection of cancer and a
      platform for personalized cancer therapy based on patient derived tumor tissue. The assay is
      able to sense activating mutations by monitoring their effect on a chip-based device.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Correct identification of tumor mutant genes</measure>
    <time_frame>up to 12 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Correct identification of tumor mutant genes, in over 85% of the cases</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Patients That Have Been Diagnosed With Cancer.</condition>
  <condition>Patients Eligible for Tumor Biopsy.</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      pathology samples of tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients that have been diagnosed with cancer and are eligible for tumor biopsy will be
        enrolled.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients that have been diagnosed positive for colon cancer.

          -  available treatment follow up during cancer treatment

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yakov Felig, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pathology lab Hadassah MC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gabi Tarcic, Dr</last_name>
    <phone>+972.2.500.1100</phone>
    <email>gabi@novellusdx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pathology Lab Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yakov Felig, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 15, 2014</lastchanged_date>
  <firstreceived_date>February 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
